Why did 9G2.SI stock fall intraday today?

The intraday fall to S$0.044 reflects weak fundamentals (EPS -0.02), high leverage (debt-to-equity 1.77), and lighter-than-average liquidity. Market comparisons and selling pressure in the Healthcare small-cap segment magnified the decline.

What is Meyka AI’s short- and long-term outlook for 9G2.SI stock?

Meyka AI's forecast model projects monthly S$0.030 (downside) and yearly S$0.086 (upside). The grade is 60.88 (Grade B, HOLD). Forecasts are model-based projections and not guarantees.

What price levels should traders watch for 9G2.SI stock?

Watch support near S$0.042 and the 200-day MA at S$0.043. Resistance sits at S$0.050–S$0.052 (50-day MA). Breaks with higher volume will define direction.

Is 9G2.SI stock a buy for income investors?

No. The company has no dividend yield and negative free cash flow per share. Income investors should avoid until profitability and cash flow improve and a stable payout policy is announced.

SG Stocks

9G2.SI stock down 8.33% to S$0.044 intraday 17 Mar 2026: key levels ahead

ByDanny Kontos March 17, 2026March 17, 2026

The 9G2.SI stock slipped 8.33% intraday to S$0.044 on 17 Mar 2026 on the SES, making it one of Singapore’s top losers today. Volume ran at 3,100,100 shares versus an average of 4,979,600, signalling heavier selling interest. The move follows weak fundamentals and low liquidity in the Healthcare, Medical – Care Facilities sector. As an AI-powered market analysis platform, Meyka AI flags the stock for short-term volatility while providing model-based forecasts to help form trading and risk plans.